INVA Stock Charts

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31

cash flows from operating activities
net income	89,908,000	63,688,000	-46,584,000	20,332,000	1,213,000	-34,685,000	36,532,000	61,531,000	82,046,000	1,280,000	34,865,000	-68,314,000	229,347,000	21,371,000	37,858,000	45,650,000	102,646,000	110,846,000	109,695,000	75,016,000	41,621,000	98,225,000	78,952,000	57,862,000	47,051,000	46,061,000	40,019,000	50,167,000	56,616,000	30,330,000	23,767,000	35,146,000	16,845,000	15,033,000	14,597,000	4,435,000	-4,584,000	-7,810,000	-10,667,000	-21,271,000	-63,564,000	-67,703,000	-46,983,000	-36,429,000	-37,360,000	-34,692,000	-37,120,000	84,594,000	-30,625,000	-25,045,000	-22,667,000	-21,222,000	-20,805,000	-22,536,000	-22,183,000	-21,692,000	-19,217,000	-20,928,000	-27,026,000	-29,764,000	-32,364,000	-45,125,000	-49,450,000	-37,837,000	-37,780,000	-41,475,000	-48,952,000	-42,211,000	-37,786,000	-31,716,000	-31,451,000	-29,171,000
adjustments to reconcile net income to net cash from operating activities:
deferred income taxes	4,949,000	-637,000	-240,000	2,821,000	-3,429,000	-15,253,000	3,244,000	5,515,000	-1,648,000	1,345,000	-812,000					10,832,000											8,508,000
amortization of capitalized fees and depreciation of property and equipment	3,488,000	3,488,000	3,488,000	3,485,000	3,480,000	3,476,000	3,510,000	3,484,000	3,483,000	3,475,000	3,479,000
amortization of acquired intangible assets	6,618,000	6,547,000	6,475,000	6,511,000	6,511,000	6,440,000	6,440,000	6,510,000	6,511,000	4,958,000	3,805,000
inventory fair value step-up adjustment included in cost of products sold	3,484,000	381,000	244,000	1,719,000	1,795,000	3,463,000	6,843,000	7,985,000	5,429,000	6,908,000	6,842,000
stock-based compensation	2,380,000	2,422,000	2,147,000	1,673,000	1,603,000	1,643,000	1,455,000	1,277,000	1,442,000	1,520,000	1,598,000	1,326,000	3,717,000	1,350,000	954,000	554,000	542,000	470,000	451,000	447,000	441,000	375,000	435,000	488,000	489,000	474,000	605,000	-874,000	1,452,000	2,169,000	2,472,000	2,427,000	2,507,000	1,718,000	2,841,000	1,864,000	1,468,000	1,822,000	1,933,000	4,732,000	7,746,000	13,535,000	6,447,000	7,162,000	6,095,000	5,830,000	5,979,000	6,235,000	7,572,000	5,593,000	5,541,000	4,496,000	5,323,000	4,497,000	4,996,000	5,274,000	5,113,000	4,756,000	3,732,000	4,914,000	5,874,000	5,505,000	5,788,000	5,347,000	4,716,000			1,689,000	1,092,000	1,434,000	1,408,000	2,361,000
amortization of debt discount and issuance costs	455,000	537,000	541,000	529,000	533,000	523,000	525,000	516,000	517,000	509,000	523,000	564,000	560,000	554,000	377,000	2,358,000											1,889,000	1,867,000	1,936,000	2,092,000
changes in fair values of equity method investments	-30,751,000	-13,082,000	13,549,000	21,256,000	18,231,000	60,108,000	-35,342,000	-9,506,000	-71,980,000	19,911,000	-15,817,000
changes in fair values of equity and long-term investments	-31,510,000	-11,280,000	65,299,000	-1,666,000	16,936,000	30,556,000	13,335,000						-1,563,000	58,600,000	9,411,000	43,176,000
acquired in-process research and development assets
other non-cash items	-21,000	-376,000	799,000	-398,000	-171,000	1,360,000	-1,513,000	253,000	-1,831,000	3,123,000	-2,062,000					-8,000
changes in operating assets and liabilities:
accounts receivable	-9,242,000	-4,252,000	3,719,000	10,154,000	-3,764,000	-12,643,000	315,000	-3,702,000	4,523,000	215,000	-6,089,000	-2,658,000
receivables from collaboration arrangement	3,984,000	-6,073,000	4,711,000		6,686,000	-5,327,000	7,750,000		8,708,000	-5,407,000	-5,642,000
inventory	6,847,000	-7,993,000	-9,153,000	-1,208,000	633,000	-2,690,000	-3,543,000	-8,207,000	902,000	-4,101,000	-598,000	-70,000
prepaid expenses	-2,805,000	-1,196,000	5,649,000	-8,413,000	-4,166,000	8,067,000	5,079,000	-6,901,000	5,806,000	3,584,000	5,440,000	-21,627,000	-2,691,000	1,623,000	1,345,000
other assets	227,000	223,000	551,000	-38,780,000	-1,010,000	971,000	633,000	-4,760,000	261,000	1,016,000	518,000
accounts payable	861,000	682,000	2,568,000	-2,038,000	2,131,000	1,149,000	-5,827,000	2,934,000	-809,000	-1,341,000	2,994,000	-866,000	-1,755,000	2,515,000	198,000	-62,000	59,000	16,000	-52,000	-557,000	428,000	73,000	112,000	-25,000	-1,104,000	995,000	133,000				352,000	-2,027,000	2,176,000				-308,000	-563,000	1,025,000				1,014,000					48,000	633,000	615,000	198,000
accrued personnel-related expenses and other accrued liabilities	-16,500,000	6,741,000	-4,809,000	7,021,000	1,973,000	-6,391,000	441,000	-426,000	2,188,000	-2,695,000	-565,000	13,622,000	-8,648,000	4,823,000	2,116,000	276,000	176,000	-936,000	227,000	552,000	267,000	111,000	-126,000	-546,000	-236,000	177,000	166,000					-510,000	752,000
accrued interest payable	-3,187,000	2,585,000	-2,589,000				-2,589,000	2,589,000	-2,589,000	2,589,000	-3,526,000	2,133,000	-2,272,000	3,101,000	-2,755,000				-2,484,000				-2,484,000	2,379,000	-2,489,000															8,454,000
income tax payable	728,000	-455,000	2,376,000	38,705,000	2,228,000	494,000	49,000	1,577,000	49,000	50,000	49,000	-23,778,000
deferred revenue	10,446,000	2,123,000	-124,000	409,000	-138,000	-132,000	-290,000	-271,000	-1,706,000																																		-428,000	-826,000	4,946,000																19,330,000	-5,305,000	26,603,000	-4,931,000	4,475,000						2,243,000	-2,740,000
net cash from operating activities	49,727,000	44,073,000	48,617,000	59,239,000	48,686,000	43,718,000	37,047,000	33,256,000	43,942,000	38,182,000	25,684,000	8,899,000	15,690,000	79,035,000	98,102,000	98,381,000	96,711,000	84,614,000	84,107,000	85,280,000	74,558,000	79,794,000	73,481,000	66,905,000	57,402,000	56,496,000	76,655,000	60,115,000	51,725,000	49,914,000	43,490,000	22,639,000	27,761,000	20,188,000	12,460,000	7,250,000	2,656,000
capex	0	0	0	0	0	0	0	-151,000	-227,000	0	-33,000	-34,000	-11,000	-13,000	-9,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
free cash flows	49,727,000	44,073,000	48,617,000	59,239,000	48,686,000	43,718,000	37,047,000	33,105,000	43,715,000	38,182,000	25,651,000	8,865,000	15,679,000	79,022,000	98,093,000	98,381,000	96,711,000	84,614,000	84,107,000	85,280,000	74,558,000	79,794,000	73,481,000	66,905,000	57,402,000	56,496,000	76,655,000	60,115,000	51,725,000	49,914,000	43,490,000	22,639,000	27,761,000	20,188,000	12,460,000	7,250,000	2,656,000
cash flows from investing activities
purchases of trading securities	-15,000,000	0	-34,674,000	-11,481,000	-5,000,000	0	-43,136,000	-5,000,000
proceeds from trading securities	0
purchases of equity investments managed by isp fund lp				0	-1,378,000	-22,136,000	-8,756,000	-6,250,000	-7,130,000	-13,893,000	-3,891,000	32,041,000	-54,925,000	-36,011,000	-2,015,000
sales of equity investments managed by isp fund lp	0	0	19,939,000	22,925,000	46,855,000	634,000	5,342,000	32,858,000	37,160,000	1,193,000	1,289,000	0	0	0	24,281,000
purchases and sales of other investments managed by isp fund lp	43,901,000	28,025,000	-19,939,000	-22,925,000	-45,477,000	21,502,000	3,414,000		-30,030,000	12,700,000	2,602,000
purchases of property and equipment				0				-151,000	-227,000	0	-33,000	-34,000	-11,000	-13,000	-9,000					0
cash paid for in-process research and development assets acquired
sale of property and equipment				3,000	0	0	98,000
net cash from investing activities	18,412,000	33,122,000	-34,674,000	-15,478,000	-5,270,000	0	-43,038,000	-5,151,000	-25,888,000	0	-35,722,000	-8,678,000	97,722,000	-2,522,000	-143,156,000	-19,905,000	0	90,021,000	-26,394,000	-315,481,000								13,522,000	9,078,000	26,513,000	-21,774,000	2,023,000	22,395,000			11,693,000	-47,875,000	34,045,000	73,710,000		-11,234,000	14,130,000						8,384,000									2,532,000				41,745,000	7,398,000	20,358,000						-12,606,000	7,540,000	9,270,000
cash flows from financing activities
repurchase of common stock				0	0	-5,208,000	-9,569,000	-14,636,000	-11,071,000	-9,286,000	-40,735,000					0
repurchase of shares to satisfy tax withholding	-25,000	-24,000	-67,000	-19,000	-18,000	-21,000	-84,000	-12,000	-11,000	-31,000	-23,000	-11,000	-12,000	-13,000	-46,000	-13,000
proceeds from issuances of common stock	194,000	1,271,000	250,000	592,000	229,000	157,000	488,000	59,000	0			28,000	1,000	81,000	260,000	1,046,000											319,000	0	340,000	114,000	3,000	177,000	8,000	6,000	162,000	173,000	3,485,000	1,425,000	1,086,000	11,843,000	5,514,000	18,272,000	113,570,000	23,442,000	2,991,000	12,416,000	214,268,000	2,532,000	1,360,000	9,824,000	11,733,000	1,436,000	2,563,000	94,057,000	1,571,000	1,349,000	4,964,000
proceeds from exercise of warrants
payment for repurchase of convertible subordinated notes due 2025
net cash from financing activities	10,842,000	1,247,000	183,000	573,000	211,000	-5,072,000	-9,165,000	-14,589,000	-11,082,000	-9,206,000	-136,962,000	-10,001,000	-96,163,000	-9,735,000	60,331,000	-12,066,000	-4,861,000	-414,260,000	-21,310,000	-2,505,000	-12,000	-11,628,000	-15,640,000	-13,749,000	-10,471,000	198,000	246,000													-7,861,000	148,416,000	18,272,000	113,569,000	23,392,000	247,864,000	12,416,000	214,255,000	2,476,000	1,307,000	9,773,000	11,671,000	1,377,000	2,529,000	94,002,000	1,530,000	1,321,000	4,935,000	2,698,000	2,607,000	166,923,000	1,332,000	3,540,000	603,000	1,175,000	839,000	2,403,000	141,557,000	1,361,000	737,000			108,440,000
net increase in cash and cash equivalents	78,981,000	78,442,000	14,126,000	44,334,000	43,627,000			13,516,000	6,972,000	28,976,000	-147,000,000			66,778,000	15,277,000	66,410,000	91,850,000	-239,625,000	36,403,000	-232,706,000	66,046,000	61,166,000	73,885,000	105,150,000	30,994,000	76,801,000	2,734,000				10,783,000	-32,174,000	41,792,000					8,393,000	44,386,000				-27,351,000	-66,827,000	171,221,000	-48,861,000						-6,620,000	-40,202,000	62,379,000				41,356,000					4,764,000	-13,342,000	832,000	-18,624,000	53,735,000					63,407,000
cash and cash equivalents at beginning of period	0	0	304,964,000	0	0	0	193,513,000	0	0	0	291,049,000	0	0	0	201,525,000	0	0	0	246,487,000	0	0	0	278,096,000	0	0	0	62,417,000	0	0	73,336,000	0	0	118,016,000	0	0	159,180,000	0	0	96,800,000	0	0	143,510,000	0	0	94,849,000	0	0	44,778,000	0	0	163,333,000	0	0	47,544,000	0	0	92,280,000	0	0	86,433,000	0	0	72,388,000	0	0	0	49,787,000	0	0	0	101,411,000	0
cash and cash equivalents at end of period	78,981,000	78,442,000	319,090,000	44,334,000	43,627,000	38,646,000	178,357,000	13,516,000	6,972,000	28,976,000	144,049,000			66,778,000	216,802,000	66,410,000	91,850,000	-239,625,000	282,890,000	-232,706,000	66,046,000	61,166,000	351,981,000	105,150,000	30,994,000	76,801,000	65,151,000	-38,611,000	60,088,000	27,138,000	10,783,000	-32,174,000	159,808,000	-19,751,000	-38,833,000	151,778,000	-70,833,000	8,393,000	141,186,000	-88,477,000	82,777,000	125,275,000	-27,351,000	-66,827,000	266,070,000	-48,861,000	146,786,000	14,310,000	-27,922,000	-57,216,000	147,874,000	-6,620,000	-40,202,000	109,923,000	4,491,000	-11,820,000	72,918,000	41,356,000	6,327,000	81,283,000	33,315,000	-31,607,000	77,152,000	-13,342,000	832,000	-18,624,000	103,522,000	27,428,000	-41,520,000	-21,620,000	85,499,000	63,407,000
loss on extinguishment of debt												0	0	0	20,662,000													2,608,000	0	3,137,000
net gain on sale of trc												0
receivables from collaboration arrangements
acquisition of intangible asset
purchases of equity method investments
purchases of equity and long-term investments								0	34,471,000	0	-35,689,000	0	1,000	-2,509,000	-56,217,000	-19,905,000	0	-19,979,000	-26,394,000
purchases of trading security managed by isp fund lp
proceeds from sale of ownership interest in trc												0
cash acquired through the consolidation of entasis												0
cash paid for the acquisition of la jolla, net of cash acquired
distributions to noncontrolling interests												0
purchase of entasis noncontrolling interest
payment for repurchase of convertible subordinated notes due 2023								0	0	0	-96,204,000	0	0	0	-165,131,000
purchases of capped call options associated with convertible senior notes due 2028												0	0	0	-21,037,000
proceeds from issuance of convertible senior notes due 2028, net of issuance costs												0	0	-256,000	252,792,000
accrued interest income added to long-term investments									0	0	-1,482,000
net decrease in cash and cash equivalents							-15,156,000
purchase and sales of other investments managed by isp fund lp														36,011,000	-132,266,000
changes in fair values of other equity and long-term investments									2,640,000	83,000	2,164,000
cash paid for the acquisition of la jolla pharmaceutical company, net of cash acquired
purchase of entasis minority interest
fair value adjustments included in cost of products sold
amortization of discount on short-term investments
amortization of lease guarantee
maturities of marketable securities																				0	4,000,000	28,000,000	54,000,000	52,999,000	103,050,000	30,000,000	27,875,000	16,500,000	23,000,000	31,875,000	8,000,000	10,000,000	26,387,000	8,000,000	16,430,000	27,671,000	30,191,000	34,045,000	25,075,000								108,763,000	45,158,000	44,925,000	48,226,000	71,250,000	31,500,000	26,000,000	44,000,000	50,000,000	20,565,000	27,500,000	110,175,000	111,982,000	12,020,000	62,451,000	-2,226,000	40,720,000
purchases of marketable securities																				0	0	0	-12,943,000	-993,000	-118,987,000
net proceeds from the issuance of variable interest entity’s equity
deferred income tax													23,274,000	-876,000	6,860,000
depreciation and amortization													5,415,000	3,591,000	3,501,000	3,456,000	3,458,000	3,458,000	3,460,000	3,458,000	3,461,000	3,458,000	3,463,000	3,474,000	3,320,000	3,541,000	3,539,000	3,468,000	3,468,000	3,468,000	3,496,000	3,495,000	3,496,000	3,491,000	3,484,000	3,483,000	3,483,000	3,483,000	3,483,000	2,530,000	2,790,000	3,400,000	1,794,000	1,992,000	1,898,000	1,890,000	1,662,000	1,910,000	2,052,000	1,757,000	1,650,000	1,560,000	1,622,000	1,515,000	1,497,000	1,324,000	1,205,000	1,588,000			834,000	820,000	871,000		1,047,000	1,061,000	980,000		1,035,000
amortization of inventory fair value adjustments included in cost of products sold
amortization of deferred royalty obligation value adjustment
other													138,000	577,000	280,000
other assets, current													-218,000	811,000	99,000
other assets, non-current													-2,780,000
net increase in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash at end of period
receivables from collaborative arrangements														-18,161,000	17,196,000	-9,440,000	2,991,000	-15,288,000	4,957,000	-1,781,000	-9,748,000	-268,000	-2,707,000	-10,216,000	-1,648,000	-8,924,000	24,647,000			14,705,000			3,120,000						311,000			2,316,000
cash acquired through the consolidation of entasis therapeutics holdings, inc.														0	23,070,000
distributions to noncontrolling interest														-9,547,000	-6,507,000	-13,099,000
supplemental disclosure of cash flow information:
cash paid for interest														0	5,411,000	0	4,966,000	0	4,967,000	0	4,966,000	0	4,967,000	300,000	5,213,000	243,000	5,218,000	6,709,000	1,972,000	8,941,000	12,246,000	10,788,000	13,522,000	13,597,000	11,008,000	13,124,000	8,215,000	4,084,000	6,870,000																									60,000	37,000	38,000	58,000	51,000	60,000	75,000	123,000	100,000
supplemental disclosure of non-cash investing and financing activities
adoption of asu 2020-06														0	28,123,000
right-of-use asset obtained through the consolidation of entasis therapeutics holdings, inc.														0	3,289,000
loss on write-off of property and equipment
prepaid expenses and other current assets																-895,000	192,000	335,000	571,000	-942,000	-53,000	177,000	140,000	-579,000	76,000	243,000	147,000	63,000			203,000			204,000			82,000	316,000	121,000										266,000	1,644,000	73,000
other long-term liabilities																								0				0	2,000	2,000	3,000	5,000	5,000																						-77,000	-77,000	620,000				650,000	4,979,000	382,000		440,000	408,000	442,000
payments of principal on senior secured term loans
payments of cash dividends to stockholders
supplemental disclosure of cash flow information
leasehold improvements
equipment, furniture and fixtures
software and computer equipment
distributions of equity and long-term investments
numerator:
net income attributable to innoviva stockholders, basic																	-16,510,000	-5,175,000	94,123,000		-48,626,000	11,407,000	65,437,000
add: interest expense on 2023 notes																	23,000
net income attributable to innoviva stockholders, diluted																	-16,487,000	-5,216,000	95,327,000		-48,639,000	11,411,000	66,617,000
denominator:
weighted-average shares used for eps calculation																	-18,965,000				34,000	89,000	101,235,000
dilutive effect of 2023 notes																	0
dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan																	25,000
net income per share
basic																	30	80	930		-480	110	650
diluted																	0	60	840		-430	100	590

changes in fair values of equity investments
purchases of equity and other long term investments
net proceeds from the issuance of variable interest entity's equity
purchases of equity investments
operating lease liability
sales of marketable securities																																		0			0	0	57,098,000										0	3,750,000	5,000,000							0	1,500,000	12,304,000	-1,421,000	31,446,000	23,863,000
proceeds from issuance of convertible senior notes due 2025
proceeds from senior secured term loans
payments of debt issuance costs and debt discount
payments of principal on non-recourse notes due 2029
contributions from (distributions to) noncontrolling interest
amortization of premium (discount) on short-term investments
payment of principal on non-recourse notes due 2029
gain on extinguishment of debt																															6,426,000
interest added to the principal balance of non-recourse notes due 2029
realized gain on sale of marketable securities
repurchase of convertible subordinated notes due 2023
proceeds from capped-call options																																		0
amortization of debt issuance costs																																714,000	687,000	724,000	715,000	699,000	769,000	763,000	764,000
amortization of premium (discount) on short term investment																																	17,000
interest added to the principal balance of the non-recourse term notes due 2029																																		0	172,000	683,000	5,613,000	6,409,000	6,427,000
gain on repurchase of convertible subordinated notes due 2023
payable to theravance biopharma, inc.
amortization of premium on short-term investments																																					134,000
inventories
accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities																																								-1,803,000	-2,574,000	4,448,000	1,531,000
deferred rent																																								41,000									404,000	1,156,000	776,000	706,000													-1,000	0	35,000	-31,000	100,000	35,000	34,000	68,000
capitalized fees paid to a related party
payments received on notes receivable																																								0			0	0	100,000				100,000	230,000	300,000	30,000	100,000	10,000	1,000	0	238,000	171,000	155,000	5,000	0	2,000	1,163,000		139,000	200,000	53,000
cash and cash equivalents contributed to theravance biopharma, inc.
change in restricted cash
proceeds from issuances of notes payable, net of debt issuance costs																																								0
supplemental disclosure of noncash information
contribution of net assets, excluding cash and cash equivalents to theravance biopharma, inc.																																								0
conversion of convertible subordinated notes into common stock
guarantee issued in connection with the spin-off
increase in intangible assets
amortization of premium on short term investment																																							233,000
payments for capitalized fees paid to a related party
amortization of premium on marketable securities
change in fair value of capped-call derivative assets
account receivables																																								0
payments for intangible assets
purchase of capped-call options
supplemental disclosures of noncash information
amortization on premium of short-term investments
purchases of available-for-sale securities
maturities of available-for-sale securities																																									118,774,000	122,399,000	48,413,000	52,230,000	54,753,000
sales of available-for-sale securities																																									0	5,000,000	5,000,000
accrued interest on convertible subordinated notes
deferred rent expense																																										116,000
proceeds from issuances of convertible subordinated notes, net of debt issuance costs
gain on marketable securities
loss on disposal of assets
change in capped-call option valuation																																											0
release of restricted cash																																														0						0			0						20,000	0	30,000
issuances of notes receivable
payments on note payable and capital lease
payment for capped calls
proceeds from issuances of convertible subordinated notes																																											-1,000	-50,000	281,673,000
supplemental non-cash financing activities:
intangible asset
gain on sale of available-for-sale securities
change in capped call option valuation																																													1,422,000
sale of available-for-sale securities																																													5,000,000
payments for capped calls
gain on sales of available-for-sale securities
forgiveness of notes receivable																																																	15,000	0	1,000							6,000	-8,000	11,000			12,000		12,000	13,000	17,000		43,000
receivables																																														23,000	-31,000	160,000			268,000
accrued personnel-related expenses, accrued interest on convertible subordinated notes and other current liabilities
purchases of short-term investments and marketable securities
sales of short-term investments and marketable securities
maturities of short-term investments and marketable securities
recognized gain on marketable securities
additions to notes receivable
accrued personnel-related expenses, accrued clinical and development expenses, accrued interest on convertible subordinated notes and other current liabilities
other liabilities, non-current
payments on notes payable and capital lease
notes receivable																																																				14,000	1,000	3,000
receivables, prepaid and other current assets																																																				597,000	1,169,000	36,000	256,000						881,000							-219,000			472,000
accounts payable and accrued liabilities																																																															2,307,000	5,463,000	-1,575,000	-2,714,000	6,029,000	4,070,000	1,963,000	107,000	3,524,000	4,831,000
accrued personnel-related expenses																																																													1,334,000			1,754,000								1,822,000
loss on sale of equipment
proceeds from sale of equipment
payments on notes payable
proceeds from issuance of convertible subordinated notes, net of issuance costs																																																										-1,000	0	166,733,000
net proceeds from issuances of common stock																																																										2,725,000	2,631,000	214,000	1,354,000	3,562,000	624,000	1,659,000	992,000	2,750,000	141,823,000	1,662,000	1,055,000	2,775,000	715,000	109,460,000
cash flows used in operating activities
depreciation																																																												1,082,000											1,086,000	1,186,000
amortization																																																												756,000
change in accrued interest receivable on marketable securities
payments on notes payable and capital leases
forgiveness (net cancellation) of notes receivable
supplemental disclosures of cash flow information
non-cash financing activity:
removal of deferred stock-based compensation
forgiveness (cancellation) of notes receivable
non-cash investing and financing activities:
other non-cash operating expenses																																																																	-31,000	496,000	11,000		157,000	-241,000	396,000
forgiveness of notes receivables																																																																							55,000	80,000
other non-cash operating activities
receivables, prepaid and other assets
other liabilities
restricted cash and cash equivalents																																																																				0	0	334,000	343,000	386,000
decrease in notes receivable																																																																				71,000	43,000	51,000	413,000	-30,000
payments on notes payables and capital leases
net proceeds from issuances of convertible preferred stock																																																																								0
conversion of convertible preferred stock to common stock																																																																								0
repurchases/issuances of common stock for notes receivable
addition to (reversal of) deferred stock-based compensation																																																																			-4,965,000
sales and maturities of marketable securities																																																																	71,764,000	33,017,000	46,127,000	48,345,000	26,144,000	56,406,000	27,052,000	28,753,000
addition to (removal of) deferred stock-based compensation																																																																	0
non-cash stock-based compensation																																																																			5,013,000
cash flows used in financing activities
deferred sublease costs
net cash (used in) provide by investing activities
proceeds from line of credit
payments on line of credit
deferred financing costs
deferred stock-based compensation																																																																								-2,047,000
addition to deferred stock-based compensation																																																																					0	0	896,000
proceeds from notes payables and capital leases
repurchases of common stock originally issued with notes receivable

The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.